Please login to the form below

Not currently logged in
Email:
Password:

Medivir buys BioPhausia

Medivir acquires BioPhausia in €62m deal as it looks to market new hepatitis C drug

Swedish company Medivir, which develops pharmaceuticals against infectious diseases caused by viruses, is to acquire specialty pharmaceutical company BioPhausia for SEK565 million (€62m).

Medivir says that the acquisition would provide it with a well-established commercial platform from which to launch its hepatitis C drug TMC435, which should be introduced on to the market by 2013.

Ron Long, chief executive of Medivir, said: "The task in hand for us is to put ourselves in a position where we can educate the market about the virtues and advantages of TMC435.”

Under the terms of the deal, Medivir is offering a mixture of cash and new shares.

13th April 2011

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
3 Monkeys Zeno

3 Monkeys Zeno is an award winning global creative communications consultancy – home to a collective of creative and strategic...

Latest intelligence

Patient engagement
Taking a holistic approach to patient care
The importance of recognising each patient as an individual...
The concordance conundrum – the tech divide
“Hello? Can you hear me? I think you are on mute” – how many times have we all heard this over the past five or so months? Not exactly the...
3 ways to increase patient retention rates in clinical trials
Retention rates are falling in clinical trials. Yes, it is a bit disheartening. But there are some straightforward things you can do to turn it around....

Infographics